Merit Medical's Tariff Refund Inflection and Organic Growth Acceleration
MMSI beats Q2, raises guidance, and confirms strategic direction amid a sector-wide tariff refund wave.
MMSI · Earnings Call · 2026-07-30
Q2: A Clean Beat and a Meaningful Raise
Merit Medical reported a strong second quarter with total revenue up 10% year-over-year (9% constant currency) and 9% organic constant currency growth, the strongest in three years. “We were pleased to deliver strong organic growth that not only exceeded the high end of our expectations, but also represents the strongest quarterly organic growth the company has delivered in 3 years.” — Martha Aronson, CEO · 2026-07-30 Non-GAAP operating margin expanded 142 basis points to 22.6%, and free cash flow hit ~$52 million in the quarter. Management raised full-year 2026 revenue and EPS guidance, with non-GAAP EPS now $4.25-$4.35 (up from $4.01-$4.15).The beat was notably balanced: Foundational products grew 6% and Therapeutic products grew 14%, with broad-based strength across Access, Vascular Intervention, Cardiac Therapies, and Endoscopy. OEM also rebounded sharply, up 15% year-over-year, contributing to the acceleration.
Tariff Refunds: From Headwind to Tailwind
The most notable thematic shift is the conversion of tariffs from a persistent headwind into a source of refunds. In Q2, Merit recognized $6.9 million of refunds within cost of sales, lifting gross margin by 262 basis points year-over-year. Raul Parra noted that even excluding the refund, gross margin exceeded guidance and that the company had "essentially received just about everything that we were expecting." “We've essentially received just about everything that we were expecting. There is still, I'd say, about $1.5 million or so that's going to come from a third-party who's our freight forwarder...” — Raul Parra, Chief Financial Officer and Treasurer · 2026-07-30This is a significant reversal from prior quarters. In Q1 2026, Raul described starting "the process of reimbursement" and still uncertain about the administration challenging refunds. “We have started the process of reimbursement. Like I said, though, I think the challenge is that the administration can still challenge the reimbursement through May.” — Raul Parra, Chief Financial Officer and Treasurer · 2026-04-30 Now the refunds are flowing through, and they are part of a broader market theme: IEEPA refunds have appeared among the top global keywords for Q2 2026, with companies like Apple and Baxter also citing tariff refund benefits. This is a shared sector tailwind, but Merit appears to be ahead of expectations.
However, the tariff story is not entirely resolved. The company increased its assumed 2026 tariff impact to $16 million (from $15 million) and noted lingering uncertainties around Section 122 and USMCA. Management widened Q3 guidance ranges to reflect this volatility. So while refunds are a positive surprise, the underlying tariff cost remains a manageable but ever-present drag.
Pipeline and Strategic Plan Build Momentum
Beyond the beat, the company is executing on multiple fronts. The integration of View Point Medical and the launch of the SCOUT MD and OneMark systems expand the oncology portfolio into the breast biopsy localization market. Management highlighted the complementary nature of the two technologies, with SCOUT MD for advanced localization and OneMark for all biopsies. The combined TAM is estimated at 1.3 million procedures annually in the U.S.Meanwhile, the strategic planning for the 2027-2029 period is underway, though management is careful to maintain focus on the current CGI targets (5-7% organic CAGR, 20-22% non-GAAP operating margin, >$400M cumulative free cash flow). Martha Aronson emphasized the team's commitment:
The CGI program remains the near-term anchor, but the strategic plan will likely reset targets for the next cycle.I want to reiterate how pleased I am that we are on track to meet our 3-year CGI goals. And while staying focused on that goal, this team is putting the hard work into our global strategic plan.
Operationally, the gross margin story continues. The company has expanded GAAP operating margin from ~8% in 2016 to 14% as of Q1 2026, a long-term trend of disciplined execution. The trend line shows a consistent upward drift, punctuated by a -5pp dip in 2022 but followed by a 7pp recovery over three years.
The stock has responded positively: the 90-day price momentum is +33%, recovering from a drawdown off the January 2025 high. The market is clearly rewarding the acceleration in growth and the improved profitability outlook.
Overall, Merit's Q2 was a standout quarter, driven by organic growth and tariff refunds, and the company is well positioned to exceed its CGI targets. The real question now is whether the strategic plan for 2027-2029 will sustain this momentum and whether the tariff relief is durable. But for now, the trajectory is clearly positive.